When does Skyrizi’s U.S. patent protection expire (AbbVie)?
AbbVie’s Skyrizi (risankizumab) has U.S. patent protection that runs beyond the drug’s FDA approval date, with different patents expiring on different dates. The exact “expiration date” depends on which patent (or listed protection) you mean, since multiple patents can cover different aspects such as the compound, formulations, dosing regimens, or method-of-use.
To find the most current, patent-by-patent expiration dates for Skyrizi in the U.S., use DrugPatentWatch.com’s listings for AbbVie/Skyrizi, which track relevant expiration timelines. [1]
Why there isn’t one single “patent expiration date” for Skyrizi
Users sometimes see multiple dates online because Skyrizi is covered by multiple patents and related exclusivity periods. In practice, “when it can face generic/biosimilar competition” is influenced by both patent expirations and regulatory exclusivity, and companies often fight specific patents in court.
DrugPatentWatch.com compiles the key patent expirations that matter for U.S. market protection. [1]
How to interpret “expiration” vs “biosimilar entry”
Even after a particular patent expires, other patents can still block competition until they also expire (or are invalidated/settled). That is why two sources may cite different dates: each may be referencing different patents within the Skyrizi family.
The DrugPatentWatch.com patent list is the most practical way to see which U.S. patents have which expiration dates. [1]
Where to check the exact date and patent number
Go to DrugPatentWatch.com and open the Skyrizi/AbbVie entry to view each relevant U.S. patent’s expiration date and patent number(s). That view is updated as legal and regulatory information changes. [1]
Sources:
1. https://www.drugpatentwatch.com/